protein therapeutics - EpiVax, Inc. - Informatics and Immunology

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

by Annie De Groot | Jun 30, 2020

2020 TCWP

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release

Designing a Better Assay – HLA-DR Binding Assays as a Tool for Immunogenicity Screening: Developing the Best Practices for Determining Immunogenicity

by Annie De Groot | Oct 9, 2018

EpiVax_AAPS HLA-binding poster epivax format[1]

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

Designing a Better Assay – HLA-DR Binding Assays as a Tool for Immunogenicity Screening: Developing the Best Practices for Determining Immunogenicity

Recent Posts

Categories